Publication | Closed Access

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

UrologyOncologyGenitourinary CancerMedicineHormonal ReceptorPharmacotherapyProstatic DiseasePharmacologyParallel First-in-human PhaseEndocrine-related Cancer